Ignacio Ferreira González

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors

Uri Tabori, Adam Shlien, Berivan Baskin et al. · Journal of Clinical Oncology · 2010 · 236 citations

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 142 citations · Full text

MRI detects myocardial iron in the human heart

Nilesh R. Ghugre, Cathleen Enriquez, Ignacio Ferreira González et al. · Magnetic Resonance in Medicine · 2006 · 123 citations · Full text

Treatment of primary CNS germinomatous germ cell tumors with chemotherapy prior to reduced dose whole ventricular and local boost irradiation

Soumen Khatua, Girish Dhall, Sharon O’Neil et al. · Pediatric Blood & Cancer · 2010 · 118 citations